As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...
Pharmaceutical Technology on MSN2d
Arbor to advance gene editing treatments with $73.9m fundingThe funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.
Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investorsFinancing extends Arbor’s cash ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...
Sarah Abo, a host on “Today,” a morning news show in Australia, said former leaders like ex-Australian Prime Minister Malcolm Turnbull need to “shut up” after Turnbull attacked Trump during an ...
The ensemble takes on the era-straddling Vespers, a crucial yet rarely performed work in the classical canon, at the ...
In a bittersweet exploration of a father-son relationship evolved through time, Bassam Mortada’s “Abo Zaabal 89”, shown at ...
ABO Energy GmbH & Co KGaA is expected to close the 2024 financial year with a group net profit of more than EUR 25 million. On 24 November 2024, the company announced in an ad hoc announcement that, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback